Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

Silke Gillessen,Ananya Choudhury,Alejo Rodriguez-Vida,Franco Nolè,Enrique Gallardo Diaz,T. Roumeguere,Gedske Daugaard,Yohann Loriot,Fred Saad,Raymond S. McDermott,Anouk Neven,Beatrice Fournier,Bertrand F. Tombal

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

2021

Silke Gillessen
Ananya Choudhury
Alejo Rodriguez-Vida
Franco Nolè
Enrique Gallardo Diaz
T. Roumeguere
Gedske Daugaard
Yohann Loriot
Fred Saad
Raymond S. McDermott
Anouk Neven
Beatrice Fournier
Bertrand F. Tombal

5002Background: The randomized phase III EORTC-1333-GUCG (NCT02194842) trial compares enzalutamide vs. a combination of Radium 223 and enzalutamide in asymptomatic or mildly symptomatic metastatic ...

Keywords:

Internal medicine
Medicine
Oncology
Asymptomatic
Enzalutamide
Radium-223

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations